Atezolizumab‐associated vitiligo‐like leukoderma in a patient with transitional cell carcinoma

Turner, Noel; Leventhal, Jonathan S.

doi:10.1111/ijd.14191

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a fraction of melanoma patients (ranging from 3.4 to 28%), vitiligo-like depigmentation (or melanoma-associated leukoderma) occurs as an adverse effect of immune checkpoint inhibition, indicating the breaking of tolerance to melanocytic self-antigens (30,31). Nevertheless, skin depigmentation has now been reported in anti-PD-1/PD-L1 treated patients with other metastatic cancers as well (32)(33)(34)(35)(36)(37). Skin depigmentation is significantly associated with a favorable prognosis in melanoma patients (17,18).…”

Section: Melanoma Immunotherapymentioning

confidence: 99%

Targeting the PD-1/PD-L1 Axis in Human Vitiligo

et al. 2020

View full text Add to dashboard Cite

Autoreactive CD8 + T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can break peripheral tolerance against self-antigens in the skin. Therapeutically enhancing immune checkpoint signaling by immune cells or skin cells, making self-reactive T cells anergic, seems a promising therapeutic option for vitiligo. Here, we review the current knowledge on the PD-1/PD-L1 pathway in vitiligo as new therapeutic target for vitiligo therapy.

show abstract